AEON Biopharma, Inc.
Close on Oct 19, 2026
- Market cap
- $11.67M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 29, 2024 | During market hours | – | – | – |
Press releases
Announcements AEON Biopharma filed with the SEC
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
market dominated by a single brand
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
AEON Biopharma Announces Pricing Of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
Material agreement · Other events · EX-99.1 to Form 8-K
market dominated by a single brand
Regulation FD disclosure · EX-99 to Form 8-K
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
Results of operations · EX-99.1 to Form 8-K
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
Unregistered share sale · Executive or director change · Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bringing Biosimilar Competition to a
Regulation FD disclosure · EX-99 to Form 8-K
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99 to Form 8-K
Fresh Data | New Capital | Simplified Structure –
Regulation FD disclosure · EX-99 to Form 8-K
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
Results of operations · EX-99.1 to Form 8-K
Accelerated Access to the $3B+
Regulation FD disclosure · EX-99 to Form 8-K
AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation - Aegis Capital Healthcare Conference
Regulation FD disclosure · EX-99 to Form 8-K
AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99 to Form 8-K
AEON Biopharma Announces CEO Transition
Executive or director change · Regulation FD disclosure · EX-99 to Form 8-K
AEON Biopharma Reports Fourth Quarter 2024 and Full Year Financial Results and Provides Corporate Update
Results of operations · EX-99 to Form 8-K
Potential biosimilar for therapeutic indications
Regulation FD disclosure · EX-99 to Form 8-K
AEON Biopharma, Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99 to Form 8-K
Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Closing of $20.0 Million Underwritten Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering
Regulation FD disclosure · EX-99.1 to Form 8-K
AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99 to Form 8-K
Potential biosimilar for therapeutic indications
Regulation FD disclosure · EX-99 to Form 8-K
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99 to Form 8-K
Potential biosimilar for therapeutic indications
Regulation FD disclosure · EX-99 to Form 8-K
AEON Biopharma Reports First Quarter 2024 Financial Results
Results of operations · EX-99 to Form 8-K
Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
SUPPLEMENTAL NOTICE OF REDEMPTION OF CERTAIN WARRANTS (CUSIP 00791X118)
Regulation FD disclosure · EX-99.1 to Form 8-K
AEON Biopharma Announces Redemption of Public Warrants
Other events · EX-99.1 to Form 8-K
NOTICE OF REDEMPTION OF CERTAIN WARRANTS (CUSIP 00791X118)
Other events · EX-99.2 to Form 8-K
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
AEON Biopharma Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Announces Topline Results from Phase 2 Trial of ABP-450
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Phase 2 Topline Results Preventive Treatment of Episodic Migraine October 2023 ABP - 450 ( prabotulinumtoxinA)
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
(episodic and chronic prophylaxis) Migraine
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Report of Independent Registered Public Accounting Firm
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K